Belapectin is a polysaccharide commercialized by Galectin Therapeutics, with a leading Phase III program in Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to Globaldata, it is involved in 11 clinical trials, of which 10 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Belapectin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Belapectin is expected to reach an annual total of $224 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Belapectin Overview

Belapectin (GR-MD-02) is under development for the treatment of NASH with advanced fibrosis, liver fibrosis and decompensated liver cirrhosis, kidney fibrosis, pulmonary arterial hypertension, arrhythmias, metastatic melanoma, lung fibrosis, prostate cancer, sarcomas, breast cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer and portal hypertension. It is administered through intravenous route and targets galectin-3. It is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that is comprised predominantly of galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. The drug candidate is developed based on the carbohydrate technology. It is a new chemical entity. It was also under development for the treatment of diabetic nephropathy, moderate to severe plaque psoriasis, cardiovascular fibrosis and severe atopic dermatitis.

Galectin Therapeutics Overview

Galectin Therapeutics is a biotechnology company. The company products include fibrosis, cancer immunotherapy, plaque psoriasis and oral galectin-3 inhibitors. It discovers, develops and commercializes therapies for fibrotic disease and cancer. Galectin Therapeutics also offers products such as GR-MD-02 and GM-CT-01. Its GR-MD-02 is a drug candidate used for treating fibrotic liver disease. and GM-CT-01 is a vaccine used to treat patients with advanced melanoma, a deadly skin cancer. The company provides research and study of the science of galectin proteins. Its products are used to treat fibrosis, galectin effects on liver fibrosis, lung fibrosis and cancer immunotherapy. Galectin Therapeutics is headquartered in Norcross, Georgia, the US.
The operating loss of the company was US$38.4 million in FY2022, compared to an operating loss of US$30.2 million in FY2021. The net loss of the company was US$38.8 million in FY2022, compared to a net loss of US$30.5 million in FY2021.

For a complete picture of Belapectin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.